Ofloxacin and the gastrointestinal tract: a potential role in the treatment of bacterial enteritis
|
|
- Osborne Rodgers
- 6 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (1990) 26, Suppl D, Ofloxacin and the gastrointestinal tract: a potential role in the treatment of bacterial enteritis R. Lang, M. Lbhner, S. Segev and E. Rubinstein Infectious Diseases Unit, Meir hospital Kfar-Saba and the Infectious Diseases Unit Cham Sheba Medical Center, Tel Aviv University School of Medicine, Israel Ofloxacin is highly active against most pathogens causing bacterial enteritis. High faecal levels are achieved readily following a single oral dose and may persist for up to five days despite partial binding by faeces. In addition, adequate ofloxacin levels persist in pancreatic secretions and bile for 12 to 14 h following oral administration. Clinical data from various centres demonstrate a prompt response when ofloxacin is administered once-daily for shigeuosis, sahnonellosis and various other enteric pathogens. These theoretical observations and clinical data suggest a potential for once-daily oral ofloxacin therapy for bacterial diarrhoea. Introduction Enteric pathogens cause significant morbidity and mortality world wide, particularly in developing countries. Many drugs have been effective in the management of bacterial diarrhoea, but the emergence of resistant pathogens, especially shigella and salmonella strains, has become a major therapeutic obstacle. Patients' compliance with prolonged therapy is also troublesome especially in underdeveloped countries where lower socioeconomic classes are commonly affected. Antibiotics that have activity against most enteric pathogens, that can be administered orally once daily, and that attain prolonged faecal concentrations may prove equally effective or superior to other drugs in the management of bacterial enteric infections. We have reviewed the data concerning the effects of ofloxacin on the gastrointestinal flora, aspects of its pharmacokinetics and its efficacy in the treatment of gastrointestinal infections and suggest its advantages as a once daily oral regimen in the management of bacterial enteritis. Ofloxacin and oral flora Effects of ofloxacin on gastrointestinal flora Single dose. Edlund et al. (1988) found only a small effect of ofloxacin, administered as a single oral dose of 400 mg, on the oral microflora of patients undergoing gastric surgery. Branhamella strains were significantly reduced in numbers and returned to normal within a few weeks but the number of streptococci, micrococci and corynebacteria remained unchanged. Colonization with Gram-negative rods occurred Reprint request* to: E. Rubinstein, MD, Infectious Diseases Unit, Sheba Medical Center, Israel O5-7453/9O/26DO $02.00/ The British Society for Antimicrobial Chemotherapy
2 46 R. Lang tf al during the study period in four of the 24 patients studied. Except for one patient in the latter group, the total concentration of Gram-negative rods isolated was < lo^/ml saliva. The anaerobic microflora was unaffected by ofloxacin except for suppression of Veillonella spp. between day 2 and day 7 in five of the 24 patients. Repeated dose. Kern, Kurrl & Vanek (1987) studied the changes in the oropharyngeal flora following prolonged ofloxacin therapy given as prophylaxis in profoundly granulocytopenic patients. A rapid and complete elimination of Enterobacteriaceae was observed within one week. Colonization with Pseudomonas aeruginosa and other Gram-negative bacilli occurred in a few patients. Coagulase-negative staphylococci were present in 15% of oropharyngeal washings and their incidence increased after the third week of ofloxacin treatment. Yeasts were found in 28% of oropharyngeal washings. Ofloxacin and gastric flora Single dose. Edlund et at. (1988) investigated the effect of a single oral dose of 400 mg ofloxacin on gastric microflora. Both anaerobic and aerobic bacteria were suppressed in the gastric secretions for 24 h. In six patients, no bacteria were detected on day 0, while five other patients had > 10 5 /ml. The number of bacteria was significantly higher when the ph was > 3-5 than it was when the ph was < 3-5 owing either to a more favourable environment for bacterial proliferation or to more optimal conditions for drug activity. During the study, colonization with yeasts was seen in 13 patients, six of whom had > lo'cfu yeasts/ml of gastric secretions. In 15 of 20 patients studied after four weeks, > 10 5 cfu yeasts/ml gastric secretions were detected. Ofloxacin and the faecal microflora Repeated doses. Pecquet et al. (1987) administered 400 mg ofloxacin daily for five days to five normal volunteers. The faecal concentration of Enterobacteriaceae dropped sharply after administration and no strains were detectable in faeces for four days following discontinuation of the drug. Six days after stopping the drug the number of Enterobacteriaceae in faeces had not returned to pretreatment levels. The same pattern was also observed for enterococci, except that return to pretreatment levels was reached within four days of stopping drug therapy. In addition, all the volunteers were colonized with Candida spp., albeit in small numbers, after four days of treatment. Anaerobic bacteria, on the other hand, remained in concentrations > cfu/g faeces. Emergence of resistance to ofloxacin in the intestinal flora was not observed. Shah et al. (1987) reported the effects of 200 mg of ofloxacin administered bd for seven days to ten volunteers. Escherichia coli were not detectable by the third day and continued undetectable until four days after drug discontinuation. Therapy had no effect on the number of anaerobic streptococci, Bacteroides spp., bifidobacteria, Eubacterium spp. and Candida spp. Clostridium difficile and staphylococci were not detected at any time. Enterococci were detected both before and after therapy in some volunteers. Chida et al. (1984) studied the effects of ofloxacin on the human faecal flora in relation to faecal drug concentrations. Five volunteers received 200 mg tds for six days. The elimination time for Enterobacteriaceae from the faeces was 48 h. More than a week was required for the reappearance of the normal enteric flora. Most anaerobes
3 Ofloxadn and the got 47 remained unaffected. Lecithinase-negative clostridia increased, while lecithinascpositive clostridia decreased during the drug administration. The microflora returned to normal only after four to five weeks. The alterations in faecal flora correlated with the faecal concentrations of ofloxadn. Van-Saene, Lemmetus & Van-Saene (1988) studied the effect of ofloxadn in 15 healthy volunteers who received 200 mg bd for two weeks. Escherichia coli was eliminated after three days of ofloxadn administration and did not reappear until five days after ofloxadn discontinuation. Ofloxadn therapy was assodated with a slight decrease in Enterococcus fecalis numbers during therapy. Half the volunteers had yeast colonization after seven days of therapy. Leigh et al. (1988) studied 11 volunteers who were given 200 mg ofloxadn bd for 3-5 days. Aerobic. Gram-negative badlli were reduced to unrecordable numbers. Gram-negative bacilli reappeared between three and 21 days after the last dose and between one and 21 days after the elimination of ofloxadn activity from the faeces. The total number of aerobes was not significantly different in eight volunteers, as the loss of Gram-negative badlli was balanced by an increase in Gram-positive organisms. No change was seen in the total number of anaerobic bacteria. No significant changes were observed in the number of yeasts. Pre- and post-treatment isolates of the major bacterial spedes were tested for drug resistance to ofloxadn; no change in MICs was detected. Kern et al. (1987) administered 200 mg ofloxadn bd to 40 patients for periods of days (mean 35 days), in combination with amphoteridn B suspension. Enterobacteriaceae were completely eliminated from the faeces within one week. Anaerobic micro-organisms were only partly affected by ofloxadn treatment. Coagulase-negative staphylococd were present in 19% of faecal samples and their inddence increased after the fourth week of treatment. Yeasts were observed in 30% of cultures. Resistant strains of aerobic Gram-negative badlli (including a few strains of Ps. aeruginosa) were acquired in four patients. Single dose. Edlund et al. (1988) studied the effect of a single oral dose of 400 mg ofloxadn on faecal flora in 24 patients undergoing gastric surgery. The flora was markedly affected during the seven days of investigation. By day 2, Enterobacteriaceae were eliminated in 12 patients and suppressed in an additional eight. Enterococd, lactobacilli, bifidobacteria, Eubacterium, Veillonella and Bacteroides spp. were also markedly suppressed. Anaerobic coed and clostridia, however, remained unaffected during the study period. In samples obtained four weeks later, the faecal flora had returned to normal. Inactivation and binding of ofloxadn by faeces Van-Saene, Van-Saene & Leek (1986) studied the inactivation of ofloxadn by faeces. The MBCs of ofloxadn for six Gram-negative badlli (Esch. coli, FQebsiella, Enterobacter, Proteus, Pseudomonas and Acinetobacter spp.) were determined in the presence of increasing concentrations (0, 10%, 20%, 30%) of faeces. After incubation, the organisms were subcultured on selective media. The MBCs of ofloxadn for Esch. coli increased dramatically to 6-2 mg/1 after adding 30% faeces. The most resistant strains were Pseudomonas and Acinetobacter spp. that had MBCs of 50 and 100 mg/1 respectively after 30% faeces was added. Reeves (1986) reported that the activity of quinolones may be markedly reduced in
4 48 R. Lang et al the gastrointestinal tract owing to binding to normal faeces. Edlund, Lindqvist & Nord (1988) measured the binding of quinoloncs to faeces. Analysis revealed two different classes of binding, one specific and the other non-specific. Their results with radioactive norfloxacin showed that the specific binding of quinolones to faeces was a reversible saturable process that increased linearly with faecal concentrations. Of interest was the demonstration that the quinolones may bind to the bacteria present in faeces rather than to faecal fibres and food remnants. They suggested that the increase in MICs, also observed by Van Saene et al. (1986), is due to the quinolone binding to the bacterial mass itself. The concentrations of quinolones assayed in faeces may, therefore, not relate to the free concentration available. In-vitro data Ofloxadn activity against enteric pathogens Bacterial pathogens associated with travellers' diarrhoea. Inagaki et al. (1989) investigated the in-vitro activity of ofloxacin against various pathogens associated with travellers' diarrhoea. Ofloxacin was highly active against 25 strains of enterotoxigenic Esch. coli (MIC*, 0-10 mg/1), 25 strains of Salmonella spp. (MIC*, 0-20 mg/1), 25 strains of Shigella spp. (MIC*, 078 mg/1), 21 strains of Campylobacter jejuni (MIQ,, 0-78 mg/1) and 12 strains of Vibrio parahaemolyticus (MIC*, 0-78 mg/1). Ofloxacin kinetics in the gastrointestinal tract Ofloxacin concentration in saliva, gastric secretions and gastric mucosa Repeated doses. Leigh et al. (1988) studied the concentration of ofloxacin in the saliva of 17 volunteers given ofloxacin 200 mg bd. Mean C,,,,, was 1-9 ±0-7 mg/1 after the first dose, rising to 2-6 ±0-7 mg/1 after the seventh dose. There was a good correlation between salivary and serum concentrations. Kern et al. (1987) found mean peak levels of ofloxacin in saliva and serum of granulocytopenic patients of 1-89 and 118 mg/1 respectively. Single dose. Edlund et al. (1988) studied ofloxacin levels in saliva, gastric secretions and gastric mucosa following a single 400 mg dose of oral ofloxacin. On day 2, eight saliva samples contained mg/1, but in others, ofloxacin could not be detected. The mean ofloxacin concentrations in gastric secretions were 240 mg/1 during surgery (day 1) and 12-4 mg/1 on day 2. Samples of gastric mucosa obtained during surgery h following ofloxacin administration contained mg/kg (mean 50mg/kg). The mean gastric mucosa/serum concentration ratio was 1-9 and was highest in tissues removed 4-5 h after drug administration. Faecal concentrations of ofloxacin Pecquet et al. (1987) gave 200 mg ofloxacin bd for five days to five volunteers. Mean peak serum concentration of ofloxacin rose from 2-8 ±1-4 mg/1 on day 1 of treatment to 4-2 ± 1-6 mg/1 on day 5. Faecal ofloxacin concentrations were much higher and peaked at 327 ±274 mg/kg faeces after four days of treatment. Five days after therapy, no activity was recovered in the faeces. Leigh et al. (1988) found faecal levels of mg/g on the second day of therapy and mg/g on day 4. Ofloxacin was detectable in the faeces of all volunteers one
5 OSoxadn and the gut 49 day after the last dose, and in six volunteers drug was still present four or five days later. No drug activity could be detected in the faeces on the sixth day following cessation of therapy. Ofloxacin penetration into mesenteric lymph nodes Stahl et al. (1988) studied the distribution of ofloxacin into mesenteric lymph nodes. Ten patients who were to undergo abdominal surgery for non-infective conditions, received four doses of 200 mg ofloxacin. Concurrent samples of the mesenteric lymph nodes and serum were obtained 4-6 h after the last dose. Ofloxacin levels ranged from 0-54 to 6-36 mg/kg. Although the data demonstrate variability between patients, both in absolute drug levels and in the ratio to serum levels, the authors conclude that the ofloxacin levels obtained were all higher than the MIC^, of Salm. typhi, a finding that could explain the clinical efficacy of ofloxacin in the management of typhoid fever. Ofloxacin concentrations in the hepatobiliary system Repeated doses. Kazmierczak et al. (1987) studied ofloxacin levels in the biliary tracts of six patients who underwent cholecystectomy or who had a T-tube drain in their common bile duct. Both groups received seven doses of ofloxacin 200 mg, given orally bd. In the patients with T-tubes, mean levels in bile were 6-5 ±31 mg/1 2-4 h after the first dose and 120±4-6mg/1 1-4h after the seventh dose. In patients undergoing cholecystectomy ofloxacin concentrations in bile from the gallbladder and common bile duct, 6h after the seventh dose, were mg/1 (mean 24-6 ± 28-5 mg/1), and mg/1 (mean 10-1 ±7-0 mg/1) respectively. The mean concentrations in the common bile duct bile, gallbladder bile and gallbladder wall were respectively, 3-9, 9-5 and 2-0 times higher than simultaneous serum concentrations. Maruyama et al. (1985) determined the concentrations of ofloxacin in bile in a group of eight patients treated with ofloxacin 200 mg bd. Biliary concentrations increased with time and then reached a plateau. The peak ofloxacin concentration in bile was approximately 9 mg/148 h after administration. The same authors also found that gallbladder tissue concentrations after repeated 200 mg doses were 5-36 ±0-68 mg/kg, and levels in gallbladder bile were mg/1. Ofloxacin accumulated in bile after multiple dosing. Single dose. Maruyama et al. (1985) also determined the concentrations of ofloxacin in bile following a single dose. Two hours after a 500 mg dose the biliary ofloxacin level was 10 mg/1. Levels of the glucuronide-conjugated metabolite ranged from 10% to 28% of the total ofloxacin excreted into the bile. After a single 200 mg dose, gallbladder tissue levels were 2-3 mg/kg, and levels in gallbladder bile were 2-57 mg/1. Duben et al. (1986) measured ofloxacin levels in gallbladder bile and wall following a single 400 mg oral preoperative dose. Mean concentrations in the bile were ±4-7 mg/1. In samples of gallbladder wall and liver tissue, the mean levels were: 4-59 ±2-72 mg/kg and 4-59 ±3-46 mg/kg respectively. Brattstrom, Malmborg & Tyden (1988) investigated the penetration of ofloxacin into the pancreatic secretions of seven patients who underwent pancreatic transplantation. Ofloxacin concentrations in pancreatic secretions were 92% of that in the serum with a mean peak level of 2-7 ±0-7 mg/1 3-6 h after drug administration. The fall in concentration with time was parallel to the decrease in serum concentration. Pederzoli et al. (1989) measured biliary ofloxacin concentrations in six patients
6 50 R. Lang et al undergoing biliary surgery, and concentrations in pancreatic secretions in five patients undergoing pancreatic surgery. All patients were given a single dose of 300 mg ofloxacin. Ofloxacin levels in bile were significantly higher than simultaneous serum concentrations. Peak levels were 7-8 mg/1 at 2 h. Concentrations in pancreatic secretions were generally lower than simultaneous serum levels. Maximum concentrations in the pancreatic secretions were 2 mg/1 at 2-3 h. Friess et al. (1989) analysed pancreatic tissue from patients undergoing surgery. The ofloxacin concentration following a 200 mg dose was 1-4 mg/kg. Selectivity of got decontamination by ofloxacin Van-Saene et al. (1988) studied selective gut decontamination by ofloxacin and ciprofloxacin. The impact on the indigenous flora was studied by measurement of /?- aspartoglycine content, yeast overgrowth and decrease in number of enterococci. Their results show that suppression of the faecal flora by ofloxacin and ciprofloxacin is more or less selective, although yeast overgrowth and a decrease in numbers of enterococci were more prominent with ciprofloxacin. Kern et al. (1987) studied selective decontamination in 40 granulocytopenic patients given ofloxacin in combination with amphotericin B suspension for days (mean 35 days). Enterobacteriaceae were completely eliminated within one week. The aerobic Gramrpositive cocci and the anaerobic microorganisms were only slightly affected by ofloxacin. Clinical data Ofloxacin in the management of gastrointestinal infections shigellosis Akalin et al. (1988) treated 21 patients with acute shigellosis with two different regimens. One group (seven patients) was treated by ofloxacin 200 mg given three times in one day. The following 14 patients received 400 mg of ofloxacin as a single dose. Clinical response in the first group was rapid and occurred in all patients by day 3 (and in most patients by day 2). Stool cultures became negative for shigellae by day 2 in all patients, and by day 1 in six cases. In the second (single dose) group 13/14 responded clinically by day 2. Twelve patients had negative stools on day 1, and 13 by day 2. In one patient the stools became negative only on day 7, despite prompt clinical recovery by day 3. The conclusion from this paper is that either mode of administration of ofloxacin is highly effective in the treatment of acute shigellosis. Our data from Israel (unpublished observations) document cure of acute shigellosis in 16 patients treated by ofloxacin 400 mg given once daily for five days. All cases were clinically and bacteriologically cured by day 3. An additional ten patients with acute salmonella enteritis were also cured by day 3 or 4 with once daily ofloxacin. Tanphaichitra, Saphaphong & Srimuang (1986) and Lo (1988) demonstrated the efficacy of ofloxacin in the management of typhoid fever and there was no subsequent chronic carriage of the pathogen. In one patient described by Loffler & Westphalen (1986) chronic excretion of non-typhoidal salmonellae that had lasted for three years was terminated by therapy with ofloxacin after many other antibiotics had failed. Our data (unpublished observations) show that three of five chronic salmonella carriers became negative following one week of therapy with once daily oral ofloxacin, while the remaining two patients became negative within two weeks. Tigaud et al. (1988) reported the treatment of 21 patients with various enteric
7 Ofloxadn and tbe gat 51 pathogens with ofloxacin 200 mg bd for six to 30 days. One group of patients comprised 11 patients with acute enterocolitis without bacteraemia, six patients with shigellosis and five with salmonellosis. In another group of ten patients, bacteraemia with Salmonella spp. was documented in nine patients and one patient had cholelithiasis with chronic Salm. typhi carriage. All patients recovered without prolonged carriage of the pathogen. Fever lysis occurred in one to six days in the first group with eradication of the pathogen by the third day. For patients with typhoid fever, the temperature settled in two to six days; blood cultures were negative by the first day of therapy, stool cultures were negative in one to six days. Discussion Therapeutic regimens in infectious diseases are often based on traditional clinical concepts. The prolonged intravenous therapy of endocarditis and osteomyelitis are two examples of time-honoured concepts that have been recently challenged because of microbiological and pharmacological data that are supported by initial clinical observations. We have tried in this review to cast light on the scientific basis for the use of ofloxacin in the management of gastrointestinal bacterial infections. We suggest a rational approach which stems from the microbiological and pharmacological data. Inagaki et al. (1989) studied the effect of ofloxacin and its optic S-(-) isomer against various pathogens associated with bacterial diarrhoea. Both compounds were effective against enteropathogenic Esch. coli, Salmonella spp., Shigella spp., Campylobacter jejuni and Vibrio parahaemolyticus. Pharmacological data (Pecquet et al., 1987; Leigh et al., 1988) demonstrate very high faecal ofloxacin levels after four days of therapy and high faecal levels were sustained for up to five days after discontinuation of therapy. Penetration of ofloxacin to sites important for the eradication of invasive bacterial pathogens, such as gallbladder tissue, bile, pancreatic fluid (Marayuma et al., 1985; Kazmierczak et al., 1987) and mesenteric lymph nodes (Stahl et al., 1988), is above the MIC of most enteropathogens. Data from other quinolones document adequate penetration into the colonic wall also. Microbiological data concerning the effect of ofloxacin on the gastrointestinal flora are abundant and reproducible. Chida et al. (1984), Kern et al. (1987), Pecquet et al. (1987), Shah et al. (1987), Leigh et al. (1988) and Van-Saene et al. (1988), all showed that repeated doses of ofloxacin cause a complete and prolonged suppression of the normal Gram-negative enteric flora without significant effects on the anaerobic and streptococcal flora. Furthermore, and relevant to this review, Edlund et al. (1988) showed that a single dose of 400 mg ofloxacin eliminated Enterobacteriaceae within two days in most patients. On the basis of these data it is reasonable to assume that elimination of enteric bacterial pathogens will follow the pattern observed for the normal Gram-negative flora, following even a single dose of 400 mg of ofloxacin. These data are further supported by initial clinical experience. A single daily dose of ofloxacin was effective in 39 patients with bacterial diarrhoea, caused by a variety of strains. In all cases symptomatology was shortened to 72 h and recovery was prompt, with no side effects observed. However, clinical data by Akalin et al. (1988) are even more impressive and indicate a good clinical response in acute shigellosis with a oneday therapeutic regimen of 400 mg ofloxacin. The clinical response occurred within h following initiation of therapy and did not differ from the response observed
8 52 R. Laaget al with more conventional therapy. Microbiological eradication was similar to that observed with traditional prolonged therapeutic regimens. We believe that the data concerning ofloxacin and the gastrointestinal tract call for a controlled clinical trial comparing a single dose of 400 mg ofloxacin with other effective regimens for enteric bacterial infections. If our hypothesis is correct, the single dose regimen is expected to be as effective as others clinically. The attractions of single dose therapy with ofloxacin for the management of bacterial diarrhoea are lower costs and better compliance, especially important in developing countries. References Akalin, H. E., Mehmet, F., Unal, S., Serin, A. & Baykal, M. (1989). Clinical efficacy of single dose or once a day treatment with ofloxacin in shigellosis. Reviews of Infectious Diseases 2, Suppl.S, Bayerdorffer, E., Simon, T. H., Bastlein, C. H., Ottenjann, R. & Kaspcr, G. (1987). Bismuth/ ofloxacin combination for duodenal ulcer. Lancet, ii, Brattstrom, C, Malmborg, A. S. & Tyden, G. (1988). Penetration of ciprofloxacin and ofloxacin into human allograft pancreatic juice. Journal of Antimicrobial Chemotherapy 22, Chida, T., Shibaoka, H., Ishizuka, I. & Nakaya, R. (1984). The effect of ofloxacin (DL8280), a new antibacterial agent of the pyridone-carboxylic acid derivative, on human fecal flora. Chemotherapy 32, Duben, W., Student, A., Jablonski, M. & Malottke, R. (1986). Zur Gewcbekonzentration und Wirksamkeit von Ofloxacin bei chirurgischen Patienten. Infection 14, Suppl. I, Edlund, C, Kager, L., Malmborg, A. S. & Sjostedt, C. E. (1988). Effect of ofloxacin on oral and gastrointestinal microflora in patients undergoing gastric surgery. European Journal of Microbiology and Infectious Diseases 17, Edlund, C, Lindqvist, L. & Nord, C. E. (1988). Norfloxacin binds to human fecal material. Antimicrobial Agents and Chemotherapy 32, Friess, H., Buchler, M., Malfertheiner, P., Isenman, R., Sclegel, P. & Beger, H. G. (1989). Concentrations of different bactericidal antibiotics in human pancreatic tissue. Digestion 43, Inagaki, Y., Horiuchi, S., Une, T. & Nakaya, R. (1989). In vitro activity of DR-3355, an optically active isomer of ofloxacin, against bacterial pathogens associated with travellers' diarrhoea. Journal of Antimicrobial Chemotherapy 24, Kazmierczak, A., Pechinot, A., Duez, J. M., Haas, O. & Favre, J. M. (1987). The biliary tract excretion of ofloxacin in man. Drugs 34, Suppl. 1, Kern, W., Kurrl, E. & Vanek, E. (1987). Ofloxacin for prevention of bacterial infections in granulocytopenic patients. Infection 15, Leigh, D. A., Walsh, B., Harris, K., Hancock, P. & Travers, G. (1988). Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. Journal of Antimicrobial Chemotherapy 22, Suppl. C, Lo, W. L. (1988). Ofloxacin in the treatment of enteric fever: a preliminary study. Journal of Antimicrobial Chemotherapy 5, Loffler, A. & Westphalen, H. G. (1986). Successful treatment of chronic salmonella excretor with ofloxacin. Lancet i Maruyama, K., Tanimura, H., Kobayashi, N., Mukaihara, S. & Saito, T. (1985). Efficacy of ofloxacin on biliary tract infections compared with other drugs. In Recent Advances in Chemotherapy. Proceedings of the 14th International Congress of Chemotherapy, Kyoto, Pecquet, S., Andermont, A. & Tancrede C. (1987). The effect of ofloxacin on fecal bacteria in human volunteers. Antimicrobial Agents and Chemotherapy 31, Pederzoli, P., Falconi, M., Bassi, C, Girclli, R., Vesentini, S., Martini, N. el al. (1989). Ofloxacin penetration into bile and pancreatic juice. Journal of Antimicrobial Chemotherapy 23, Reeves D. S. (1986). The effect of quinolone antibacterialj on the gastointcstinal flora compared with that of other antibacterials. Journal of Antimicrobial Chemotherapy 18, Suppl. D,
9 Ofloxacin and tbe got 53 Shah, P. M., Enzcnsberger, R., Glogau, O. & Knothe, H. (1987). Influence of oral tiprofloxatin or ofloxacin on fecal flora of healthy volunteers. American Journal of Medicine 82, Suppl. 4A, Stahl, J., Laclerq, M. A., Lefebvrc, R., Yver, J. P., Bra, J. P., Letoublon, C. et al. (1988). Distribution of ofloxacin into mesenteric lymph nodes. Review of Infectious Disease 10, Suppl. 1, Tanphaichitri, D., Saphaphong, S. & Srimuang, S. (1986). Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections. Infection 14, Tigaud, S., Lucht, F., Pyeramond, D. & Noel, F. (1988). Use for ofloxacin for the treatment of enteric infections. Reviews of Infectious Diseases 10, Suppl. 1, 207. Van-Saene, H. K. F., Lemmetus, S. E. B. & Van-Saene, J. J. M. (1988). Gut decontamination by oral ofloxacin and ciprofloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 22, Suppl. C, Van-Saene, J. J. M., Van-Saene, H. K. F. & Leek, C. F. (1986). Inactivation of quinolones by feces. Journal of Infectious Diseases 153,
ECOLOGICAL IMPACT OF NARROW SPECTRUM ANTIMICROBIAL AGENTS COMPARED TO BROAD SPECTRUM AGENTS ON THE HUMAN INTESTINAL MICROFLORA CARL ERIK NORD
Old Herborn University Seminar Monograph 3: Consequences of antimicrobial therapy for the composition of the microflora of the digestive tract. Editors: Carl Erik Nord, Peter J. Heidt, Volker Rusch, and
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationEffect of dalbavancin on the normal intestinal microflora
Journal of Antimicrobial Chemotherapy (00), 1 doi:10.109/jac/dkl1 Advance Access publication 1 July 00 Effect of dalbavancin on the normal intestinal microflora Carl Erik Nord*, Gundars Rasmanis and Elisabeth
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationDrug resistance in relation to use of silver sulphadiazine cream in a burns unit
J. clin. Path., 1977, 30, 160-164 Drug resistance in relation to use of silver sulphadiazine cream in a burns unit KIM BRIDGES AND E. J. L. LOWBURY From the MRC Industrial Injuries and Burns Unit, Birmingham
More informationEnteric Bacteria. Prof. Dr. Asem Shehabi Faculty of Medicine University of Jordan
Enteric Bacteria Prof. Dr. Asem Shehabi Faculty of Medicine University of Jordan Enteric Bacteria General Characteristics: Gram-ve Bacilli, Facultative Anaerobes, Intestinal Normal Flora.. Humans, Animals,
More informationAnaerobic and microaerophilic gram-positive cocci Peptococcus species, Peptostreptococcus species, Microaerophilic streptococci
CLINDACIN Composition Each capsule contains Clindamycin (as hydrochloride) 150 mg Capsule Action Clindamycin bind exclusively to the 50S subunit of bacterial ribosomes and suppress protein synthesis. Clindamycin
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationVCH PHC SURGICAL PROPHYLAXIS RECOMMENDATIONS
VCH PHC SURGICAL PROPHYLAXIS RECOMMENDATIONS CARDIAC Staphylococcus aureus, S. epidermidis, except for For patients with known MRSA colonization, recommend decolonization with Antimicrobial Photodynamic
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationInfection Comments First Line Agents Penicillin Allergy History of multiresistant. line treatment: persist for >7 days they may be
Gastrointestinal Infections Infection Comments First Line Agents Penicillin Allergy History of multiresistant Campylobacter Antibiotics not recommended. Erythromycin 250mg PO 6 Alternative to first N/A
More informationAPPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.
APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAMEAND DOSAGE FORM: DALACIN C TM 150 mg (Capsules) COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin
More informationObjectives. Basic Microbiology. Patient related. Environment related. Organism related 10/12/2017
Basic Microbiology Vaneet Arora, MD MPH D(ABMM) FCCM Associate Director of Clinical Microbiology, UK HealthCare Assistant Professor, Department of Pathology and Laboratory Medicine University of Kentucky
More informationRole of the nurse in diagnosing infection: The right sample, every time
BROUGHT TO YOU BY Role of the nurse in diagnosing infection: The right sample, every time The module has been written by Shanika Anne-Marie Crusz and Amelia Joseph Authors affiliation: Department of Clinical
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationSecondary peritonitis
Secondary peritonitis Caused by spillage of gastrointestinal microorganisms into the peritoneal cavity secondary to loss of the integrity of the mucosal barriers Etiology: perforation of peptic ulcer traumatic
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationIntra-abdominal anaerobic infections. Diagnostics and therapy
Intra-abdominal anaerobic infections. Diagnostics and therapy Elisabeth Nagy MD. PhD. DSc. Institute of Clinical Microbiology, Faculty of Medicine, University of Szeged 4th ESCMID School, Szeged, Hungary
More informationChapter Anaerobic infections (individual fields): prevention and treatment of postoperative infections
J Infect Chemother (2011) 17 (Suppl 1):62 66 DOI 10.1007/s10156-010-0141-x GUIDELINES Chapter 2-5-1. Anaerobic infections (individual fields): prevention and treatment of postoperative infections Ó Japanese
More informationMICRO-ORGANISMS by COMPANY PROFILE
MICRO-ORGANISMS by COMPANY PROFILE 2017 1 SAPROPHYTES AND PATHOGENES SAPROPHYTES Not dangerous PATHOGENES Inducing diseases Have to be eradicated WHERE ARE THERE? EVERYWHERE COMPANY PROFILE 2017 3 MICROORGANISMS
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationAntimicrobial Agents and Intestinal Microflora
Bifidobacteria Micrlora Vol. 1(1), 25-37, 1982 Antimicrobial Agents and Intestinal Micrlora Rintaro NAKAYA, Toshio CHIDA, and Harumi SHIBAOKA Department Microbiology, Tokyo Medical and Dental University
More informationClassification of Bacteria
Classification of Bacteria MICROBIOLOGY -TAXONOMY Taxonomy is the system to classify living organisms Seven groups kingdom, phylum or div, class, order, family, genus, species Binomial system of nomenclature
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationRecommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee
VICH GL27 (ANTIMICROBIAL RESISTANCE: PRE-APPROVAL) December 2003 For implementation at Step 7 - Final GUIDANCE ON PRE-APPROVAL INFORMATION FOR REGISTRATION OF NEW VETERINARY MEDICINAL PRODUCTS FOR FOOD
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationEcological impact of the des-f(6)-quinolone, BMS , on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M.
ORIGINAL ARTICLE Ecological impact of the des-f(6)-quinolone, BMS-284756, on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M. Grasela 2 1 Department of Microbiology, Pathology and
More informationOverview of Infection Control and Prevention
Overview of Infection Control and Prevention Review of the Cesarean-section Antibiotic Prophylaxis Program in Jordan and Workshop on Rational Medicine Use and Infection Control Terry Green and Salah Gammouh
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationPart II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)
Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet
More informationTyphoid fever - priorities for research and development of new treatments
Typhoid fever - priorities for research and development of new treatments Isabela Ribeiro, Manica Balasegaram, Christopher Parry October 2017 Enteric infections Enteric infections vary in symptoms and
More informationDiabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals
Diabetic Foot Infection Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals History of previous amputation [odds ratio (OR)=19.9, P=.01], Peripheral vascular disease (OR=5.5, P=.007)
More information6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS
6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although
More informationBacteriology. Mycology. Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, Surrey. KT3 6NB. Order Number:
Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, urrey. KT3 6NB Bacteriology Lactobacillus species 3+ Escherichia coli 4+ Bifidobacterium 3+ gamma haemolytic treptococcus NP 4+
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More information4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals
1.B1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMOXYCOL Soluble Powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin trihydrate 640.0
More informationMICROBIOLOGY of RAW MILK
MICROBIOLOGY of RAW MILK Introduction Milk and other dairy products are of superior quality and safety Milk Quality 00 29 49 69 89 99 Microbial in Raw Milk GENERAL ASPECTS Milk is a good source of nutrients
More informationAntimicrobial resistance at different levels of health-care services in Nepal
Antimicrobial resistance at different levels of health-care services in Nepal K K Kafle* and BM Pokhrel** Abstract Infectious diseases are major health problems in Nepal. Antimicrobial resistance (AMR)
More informationGASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT
GASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT DRAFT AS CURRENTLY OUT FOR CONSULTATION BUT CAN BE UTILISED IN PRESENT FORMAT Name & Title Of Author: Date Revised: Approved by Committee/Group:
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationnumber Done by Corrected by Doctor Dr.Malik
number 27 Done by Fatimah Farhan Corrected by Basil Al-Bakri Doctor Dr.Malik Note: anything in red is just extra info and you will not be asked about it in the exam. In this sheet we will continue talking
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationSummary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Enrotab 50 mg tablets for dogs
Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotab 50 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance Enrofloxacin
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.04 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important
More informationAminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.
Aminoglycosides The only bactericidal protein synthesis inhibitors. They bind to the ribosomal 30S subunit. Inhibit initiation of peptide synthesis and cause misreading of the genetic code. Streptomycin
More informationAntibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University
Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine Mike Apley Kansas State University Changes in Food Animal Antibiotic Use How the uses of antibiotics in
More informationApplication of sewage in pisciculture in order to augment fish production has been an
Conclusions Application of sewage in pisciculture in order to augment fish production has been an ancient practice in India and other countries like i.e. China, Egypt and Europe. Possible health hazard
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationEffect of Lactobacillus F19 on the emergence of antibioticresistant microorganisms in the intestinal microflora
Journal of Antimicrobial Chemotherapy (2004) 54, 791 797 DOI: 10.1093/jac/dkh406 Advance Access publication 25 August 2004 Effect of Lactobacillus F19 on the emergence of antibioticresistant microorganisms
More informationThe Rise of Antibiotic Resistance: Is It Too Late?
The Rise of Antibiotic Resistance: Is It Too Late? Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine None DISCLOSURES THE PROBLEM Antibiotic resistance is one of the
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin
More informationEuropean Public MRL assessment report (EPMAR)
18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3
More informationPharm 262: Antibiotics. 1 Pharmaceutical Microbiology II DR. C. AGYARE
Pharm 262: 1 Pharmaceutical Microbiology II Antibiotics DR. C. AGYARE Reference Books 2 HUGO, W.B., RUSSELL, A.D. Pharmaceutical Microbiology. 6 th Ed. Malden, MA: Blackwell Science, 1998. WALSH, G. Biopharmaceuticals:
More informationCell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017
Cell Wall Inhibitors Assistant Professor Naza M. Ali Lec 3 7 Nov 2017 Cell wall The cell wall is a rigid outer layer, it completely surrounds the cytoplasmic membrane, maintaining the shape of the cell
More informationUSA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only
USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationTHE STABILITY OF E1VROFLOXA CIN University Undergraduate Research Fellow. A Senior Thesis. Texas ASM University.
THE STABILITY OF E1VROFLOXA CIN A Senior Thesis By Meagan A. Dodge 1997-98 University Undergraduate Research Fellow Texas ASM University Group: Biology THE STABILITY OF ENROFLOXACIN MEAGANA, DODGE Submitted
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationChapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
More informationBactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationSSI PREVENTION - CORRECT AND SAFE SURGICAL ANTIBIOTIC PROPHYLAXIS
SSI PREVENTION - CORRECT AN SAFE SURGICAL ANTIBIOTIC PROPHYLAXIS Things you should know! There is wide consensus on specific procedures that warrant antibiotic prophylaxis as well as in which procedures
More informationBacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups
Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationTest Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants
Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationMike Apley Kansas State University
Mike Apley Kansas State University 2003 - Daptomycin cyclic lipopeptides 2000 - Linezolid - oxazolidinones 1985 Imipenem - carbapenems 1978 - Norfloxacin - fluoroquinolones 1970 Cephalexin - cephalosporins
More informationamoxycillin/clavulanate vs placebo in the prevention of infection after animal
Archives of Emergency Medicine, 1989, 6, 251-256 A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites P. H. BRAKENBURY & C. MUWANGA Accident
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationTHE QUINOLONES. Third Edition. Edited by VINCENT T. ANDRIOLE. Yale University School of Medicine ACADEMIC PRESS
THE QUINOLONES Third Edition Edited by VINCENT T. ANDRIOLE Yale University School of Medicine ACADEMIC PRESS San Diego London Boston New York Sydney Tokyo Toronto CONTENTS Contrihuttirs Prc face xv xix
More informationApproved by the Food Safety Commission on September 30, 2004
Approved by the Food Safety Commission on September 30, 2004 Assessment guideline for the Effect of Food on Human Health Regarding Antimicrobial- Resistant Bacteria Selected by Antimicrobial Use in Food
More informationBIOL 2900 D 4.00 Microbiology in Health/Disease
SYLLABUS BIOL 2900 - D Spring, 2017 Course: Microbiology in Health and Disease Instructor: Prafull C. Shah Office Hours: Before or after classes, or by appointment by Email to pcshah@valdosta.edu. Semester
More informationAntibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients.
Antibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients. Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience,
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/389/98-FINAL July 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ENROFLOXACIN (extension to
More informationnumber Done by Corrected by Doctor Dr. Malik
number 25 Done by م ها أبو عجمي ة OsamsaAlZoubi Corrected by - Doctor Dr. Malik Antibiotic Misuse There are many ways of antibiotics misuse: Taking antibiotics when they are not needed: Antibiotics are
More informationMeropenem for all? Midge Asogan ICU Fellow (also ID AT)
Meropenem for all? Midge Asogan ICU Fellow (also ID AT) Infections Common reason for presentation to ICU Community acquired - vs nosocomial - new infection acquired within hospital environment Treatment
More informationChapter Anaerobic infections (individual fields): intraperitoneal infections (acute peritonitis, hepatobiliary infections, etc.
J Infect Chemother (2011) 17 (Suppl 1):84 91 DOI 10.1007/s10156-010-0146-5 GUIDELINES Chapter 2-5-4. Anaerobic infections (individual fields): intraperitoneal infections (acute peritonitis, hepatobiliary
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationLiofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms
Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms Microbiology Products since 1983 Liofilchem Chromatic ESBL Selective
More informationCourse: Microbiology in Health and Disease Office Hours: Before or after Class or by appointment
SYLLABUS BIOL 2900 SECTIONS C AND D Spring, 2011 Course: Microbiology in Health and Disease Office Hours: Before or after Class or by appointment Semester Begins on January 10, 2011 and ends on May 2,
More information